On March 18, Luculent Group's investor inspection and exchange activities were successfully held in Zhuhai Breast Milk Oligosaccharide (HMOs) project production base. Chen Jianxiang, Chairman of Luculent Group, Zhou Cunquan, Vice President of Luculent Group, Yan Wujun, Secretary of the Board of Directors, Chen Lei, General Manager of Synthetic Biology Intelligent Manufacturing Division, and other senior executives of the company had an in-depth exchange with more than 30 investor representatives, as well as guests from mainstream securities institutions and fund companies such as China Merchants Securities, CITIC Securities, Qianhai Open Source Fund, etc., on the Group's business status, future development strategy and the development of synthetic biology intelligent manufacturing business.

During the inspection, under the leadership of Chen Jianxiang, Chairman of the Group, the research guests visited the R&D center and production workshop of Luculent Group's HMOs Zhuhai project. As an important innovation base for the Group's synthetic biology intelligent manufacturing business, the Zhuhai project has built an industry-leading synthetic biology R&D innovation laboratory and a high-standard production line, and is responsible for the R&D, production and sales of HMOs series products.

During the discussion and exchange session, Chen Jianxiang gave a detailed introduction to the guests and investment institutions on the R&D, main business and future development of Luculent Group's biotechnology. He said that for more than 20 years, Luculent Group has continued to promote the two main businesses of biomass resource regeneration and synthetic biology intelligent manufacturing based on the same technology platform, the biotechnology R&D center, and has formed a steady operation trend of "one foundation, two flowers bloom", and the development potential has been continuously enhanced.

Chen Jianxiang pointed out that Luculent Group has a solid foundation in biotechnology, and since its establishment in 2001, Luculent has always adopted microbial fermentation technology, microbial purification technology and biological enzymatic technology to continuously produce and iterate biodiesel, clean electricity, biogas and other resource products. At present, with many advantages such as leading technology, stable operation and high profits, Luculent Group has become a leading enterprise in the field of biomass waste resource recycling.

Focusing on the synthetic biology intelligent manufacturing business, Luculent Group has established an independent subsidiary, Zhongke Langjian, through technical cooperation with the Chinese Academy of Sciences and other institutions, to create a high-standard synthetic biology experimental platform, droplet microfluidic experimental platform and bioinformatics AI technology platform, and to develop and produce high-end synthetic biological health products such as HMOs (human milk oligosaccharides) with the assistance of AI technology, so as to apply biotechnology in a broader market space.

At the same time, Luculent also cooperates with the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences to invest in the construction of the "National Biomanufacturing Industry Innovation Center", and joins hands with leading biotechnology enterprises, research institutions and other parties to jointly build an open, shared, forward-looking and cross-cutting innovation platform, and accelerate the basic research, platform construction and transformation and application of synthetic biology.

Subsequently, Chen Jianxiang also gave a detailed introduction to the technical level, scale and industrialization process of Luculent Group's HMOs project. He said that Zhongke Langjian is the first batch of enterprises in China to realize the pilot scale-up of lactose N tetraose (LNT) and lactose N neotetraose (LNnT) in HMOs (breast milk oligosaccharides), and the quality has reached the best standard of product specifications in the industry, and the purity and fermentation product concentration of HMOs are in the leading position in the industry. In January 2024, a variety of HMOs production strains independently developed by Longjian obtained safety certification from the Ministry of Agriculture and Rural Affairs of China.

During the discussion, Dr. Chen Lei, General Manager of the Synthetic Biology Intelligent Manufacturing Division of Luculent Group, gave a supplementary introduction to the origin, technology and planning of HMOs business, and vividly and deeply expounded the long-term accumulation of Luculent Group in the field of biotechnology.

During the interactive session, the senior executives of the Group also gave detailed answers to some detailed questions about Luculent's HMOs project and biomass resource recycling business that investors are concerned about.

This event is the first time that Luculent Group has disclosed the progress of synthetic biology intelligent manufacturing business offline, which is of great significance for investors to further understand the company's R&D strength, operation level and future development. In the future, Luculent Group will continue to strengthen exchanges with investors, actively convey the company's development strategy, and enhance the recognition of the capital market.